The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2-breast cancer or TNBC

被引：0
|
作者：
Sarina, Piha-Paul
Xu, Binghe
Fan, Ying
Yuan, Yuan
Lavasani, Sayeh
Mortimer, Joanne
Goel, Sanjay
Tsimberidou, Apostolia
Ibrahim, Nuhad
Abouharb, Sausan
Barcenas, Carlos
Lheme, Adaeze
Karp, Daniel
Ahnert, Jordi Rodon
Dumbrava, Ecaterina
Fan, Jean
Peng, Peng
Sun, Caixia
Wang, Hui
Hennessy, Katie
Fu, Ximei
Xu, Ruolan
Ni, Shumao
Wu, Frank
Meric-Bernstam, Funda
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-RF01-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
RF01-07
引用
收藏
页数：3
相关论文
共 50 条
  • [31] PATIENT REPORTED HEALTH UTILITY IN HR+/HER2-ADVANCED/METASTATIC BREAST CANCER
    Mitra, D.
    Wood, R.
    De Courcy, J.
    Iyer, S.
    VALUE IN HEALTH, 2016, 19 (07) : A749 - A749
  • [32] Optimizing CDK4/6 inhibitors in advanced HR+/HER2-breast cancer: A personalized approach
    Fontanella, Caterina
    Giorgi, Carlo Alberto
    Russo, Stefania
    Angelini, Silvia
    Nicolardi, Linda
    Giarratano, Tommaso
    Frezzini, Simona
    Pestrin, Marta
    Palleschi, Dario
    Bolzonello, Silvia
    Parolin, Veronica
    Haspinger, Eva R.
    De Rossi, Costanza
    Greco, Filippo
    Gerratana, Lorenzo
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 180
  • [33] Biological effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+, HER2-breast cancer
    Hurvitz, S.
    Martin, M.
    Fernandez Abad, M.
    Chan, D.
    Rostorfer, R.
    Petru, E.
    Barriga, S.
    Costigan, T. M.
    Caldwell, C. W.
    Nguyen, T.
    Press, M.
    Slamo, D.
    CANCER RESEARCH, 2017, 77
  • [34] Quality care of patients with HR+/HER2-breast cancer: Insights from an implementation science program
    McKinnon, Kelly E.
    O'Shaughnessy, Joyce
    Gurska, Lindsay
    Carter, Jeffrey D.
    Heggen, Cherilyn
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [35] Conventional Tools for Predicting Satisfactory Response to Neoadjuvant Chemotherapy in HR+/HER2-Breast Cancer Patients
    Oprea, Adela Luciana
    Gulluoglu, Bahadir
    Aytin, Yusuf Emre
    Eren, Ozgur Can
    Aral, Canan
    Szekely, Tiberiu-Bogdan
    Tastekin, Ebru
    Kaya, Handan
    Bademler, Sueleyman
    Karanlik, Hasan
    Sezer, Atakan
    Ugurlu, Mustafa Umit
    Turdean, Sabin Gligore
    Georgescu, Rares
    Marginean, Claudiu
    BREAST CARE, 2023, 18 (05) : 344 - 353
  • [36] Abemaciclib for Patients with advanced or metastatic HR plus Breast Cancer and HER2-Breast Cancer Benefits in Overall Survival - even in Patients with visceral Metastases
    Ruedesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (06)
  • [37] Comparison of ctDNA profiles from HR+/HER2-low and HR+/HER2-0 advanced breast cancer patients
    Dobric, N.
    Dandachi, N.
    Klocker, E. V.
    Suppan, C.
    Graf, R.
    Hasenleithner, S.
    Jost, P. J.
    Heitzer, E.
    Balic, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S387 - S387
  • [38] Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+Breast Cancer
    Shagisultanova, Elena
    Gradishar, William
    Brown-Glaberman, Ursa
    Chalasani, Pavani
    Brenner, Andrew J.
    Stopeck, Alison
    Parris, Hannah
    Gao, Dexiang
    McSpadden, Tessa
    Mayordomo, Jose
    Diamond, Jennifer R.
    Kabos, Peter
    Borges, Virginia F.
    CLINICAL CANCER RESEARCH, 2023, 29 (24) : 5021 - 5030
  • [39] Efficacy and safety of abemaciclib in combination with endocrine therapy for HR+/HER2-advanced or metastatic breast cancer: A systematic review and meta-analysis.
    Altaf, Faryal
    Qureshi, Zaheer
    Jamil, Abdur
    Siddique, Rimsha
    Fatima, Eeshal
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] REAL-WORLD DATA: IMPACT OF LOW HER-2 EXPRESSION IN METASTATIC HR+/HER2-BREAST CANCER TREATED WITH PALBOCICLIB
    Montenegro, Maria Alexandra
    Simao, Diana Cardoso
    Mendes, Jose Leao
    Fernandes, Leonor Raposo
    Martins, Maria Manuela
    Da Luz, Ricardo
    Oliveira, Sonia Duarte
    BREAST, 2023, 71 : S57 - S58
12345